Efficacy of risedronate on clinical vertebral fractures within six months

References

• Melton LJ III. Epidemiology of spinal osteoporosis. Spine 1997;22:2S–11S
   Google Scholar
• Cooper C, Atkinson EJ, O’Fallon, WM, et al. Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985–1989. J Bone Miner Res 1992;7: 221–7
   Google Scholar
• Huang C, Ross PD, Wasnich RD. Vertebral fracture and other predictors of physical impairment and health care utilization. Arch Intern Med 1996;156:2469–75
   Google Scholar
• Nevitt MC, Ettinger B, Black DM, et al. The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med 1998;128:793–800
   PubMed Web of Science ®Google Scholar
• Ross PD, Davis JW, Epstein RS, et al. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991;114:919–23
   PubMed Web of Science ®Google Scholar
• Nevitt MC, Ross PD, Palermo L, et al. Association of prevalent vertebral fractures, bone density, and alendronate treatment with incident vertebral fractures: effect of number and spinal location of fractures. Bone 1999;25:613–9
   PubMed Web of Science ®Google Scholar
• Kotowicz MA, Melton LJ III, Cooper C, et al. Risk of hip fracture in women with vertebral fracture. J Bone Miner Res 1994;9:599–604
   PubMed Web of Science ®Google Scholar
• Burger H, van Daele PL, Algra D, et al. Vertebral deformities as predictors of nonvertebral fractures. BMJ 1994;309:991–2
   PubMed Web of Science ®Google Scholar
• Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001;285:320–3
   PubMed Web of Science ®Google Scholar
• Cauley JA, Thompson DE, Ensrud KC, et al. Risk of mortality following clinical fractures. Osteoporosis Int 2000;11:556–61
   PubMed Web of Science ®Google Scholar
• Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal women. N Engl J Med 1995;333:1437–43
   Google Scholar
• Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535–41
   PubMed Web of Science ®Google Scholar
• Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 1998;280:2077–82
   PubMed Web of Science ®Google Scholar
• Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA 1999;282(7):637–45
   PubMed Web of Science ®Google Scholar
• Reginster J-Y, Minne HW, Sorensen OH, et al. Randomised trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporosis Int 2000;11:83–91
   Google Scholar
• Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized, controlled trial. JAMA 1999;282:1344–52
   PubMed Web of Science ®Google Scholar
• Genant HK, Wu CY, van Kuijk C, et al. Vertebral fracture assessment using a semiquantiaqtive technique. J Bone Miner Res 1993;8:1137–48
   PubMed Web of Science ®Google Scholar
• Wallach S, Cohen S, Reid DM, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000;67:277–85
   PubMed Web of Science ®Google Scholar
• Harrington T, Baylink DJ, Ste-Marie L-G. Risedronate rapidly reduces the risk for non-vertebral fractures in women with postmenopausal osteoporosis Calcif Tissue Int. 2003; Available at: http://www.springerlink.com/media/6804k1babx4yvlcb8ue3/ contributions/a/j/7/0/AJ705HME3WD0FMH1_html/fulltext.html
   Google Scholar
• Li Z. A method to assess the proportion of treatment effect explained by a surrogate endpoint. Statistics in Medicine 2001;20:3175–88
   PubMed Web of Science ®Google Scholar
• Sarkar S, Mitlak BH, Wong M, et al. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 2002;17(1):1–10
   PubMed Web of Science ®Google Scholar
• Dufrense TE, Chmeilewski PA, Manhart MD, et al. Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography. Calcif Tissue Int 2003;73(5):423–32
   PubMed Web of Science ®Google Scholar
• Boivin G, Meunier PJ. Changes in bone remodeling rate influences the degree of mineralization of bone. Connect Tissue Res 2002;43:535–7
   PubMed Web of Science ®Google Scholar
• Nevitt MC, Ross PD, Palermo L, et al., for the Fracture Intervention Trial Research Group. Association of prevalent vertebral fractures, bone density and alendronate treatment with incident vertebral fractures: effect of number and spinal location of fractures. Bone 1999;25:613–9
   Google Scholar
• Singer K, Edmonston S, Day R, et al. Prediction of thoracic and lumbar vertebral body compressive strength: correlations with bone mineral density and vertebral region. Bone 1995;17:167–74
   PubMed Web of Science ®Google Scholar